STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
IPO Year:
Exchange: NASDAQ
Website: staar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $17.00 | Equal Weight | Wells Fargo |
| 2/12/2025 | Buy → Hold | Jefferies | |
| 2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho |
| 2/12/2025 | Buy → Neutral | BTIG Research | |
| 2/12/2025 | Outperform → Mkt Perform | William Blair | |
| 7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley |
| 6/11/2024 | $46.00 | Neutral → Buy | BTIG Research |
| 3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel |
| 12/5/2023 | Buy → Hold | Needham | |
| 12/4/2023 | $35.00 | Equal-Weight | Morgan Stanley |
Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00
Jefferies downgraded STAAR Surgical from Buy to Hold
Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously
BTIG Research downgraded STAAR Surgical from Buy to Neutral
William Blair downgraded STAAR Surgical from Outperform to Mkt Perform
Morgan Stanley downgraded STAAR Surgical from Equal-Weight to Underweight and set a new price target of $37.00 from $50.00 previously
BTIG Research upgraded STAAR Surgical from Neutral to Buy and set a new price target of $46.00
Stifel upgraded STAAR Surgical from Hold to Buy and set a new price target of $50.00 from $30.00 previously
Needham downgraded STAAR Surgical from Buy to Hold
Morgan Stanley initiated coverage of STAAR Surgical with a rating of Equal-Weight and set a new price target of $35.00
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. "We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago," said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical's Board of Directors. "We look forward to Lilian's contributions as a former institutional shar
10-Q - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
DEF 14A - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
10-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K/A - STAAR SURGICAL CO (0000718937) (Filer)
3 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13D/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2025 Financial Results Webcast Date: Wednesday, May 7, 2025 Time: 5:15 p.m. ET Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp The live webcast, including an option to pre-register, can be accessed at the
Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR's Chief Financial Officer from 2017- 2020, to serve as Interim Chief Financial Officer Patrick F. Williams Steps Down as Chief Financial Officer Keith Holliday Retires as Chief Technology Officer STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following changes to right size and realign its leadership structure to better address market needs: Warren Foust, Chief Operating Officer, has been promoted to the newly created role o
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day. Event: 4th Annual BTIG Ophthalmology Day Management Attendee: Thomas G. Frinzi, Chair of the Board, President and CEO Date: Monday, December 2, 2024 Fireside Chat: 4:00 p.m. ET / 1:00 p.m. PT Location: Attendance by invitation only from BTIG, the sponsoring brokerage firm. About STAAR Surgical STAAR, which has been dedicated solely to ophthalmic surgery for over 40 y
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN. Event: Stephens Annual Investment Conference (NASH2024) Management Attendee: Patrick F. Williams, Chief Financial Officer Date: Wednesday, November 20, 2024 Time: 11:00 a.m. ET / 8:00 a.m. PT Location: Live Webcast The live webcast link includes an option to pre-register. An online replay of the webcast will also be
Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030604379/en/ Third Quarter 2024 Overview Net sales of $88.6 million, up 10% from prior year quarter ICL sales of $89.1 million
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2025 Financial Results Webcast Date: Wednesday, May 7, 2025 Time: 5:15 p.m. ET Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp The live webcast, including an option to pre-register, can be accessed at the
Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: https://staar-surgical-2q24-earnings.open-exchange.net/ STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. The
EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ:K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview Net sales up 5% to $77.4 million and up 7% in constant currency ICL sales up 9% and units up 2% Gross margin at 78.9% vs. 78.3% year ago Net loss of $3.3 million or $0.07 loss per share vs. net
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close. STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants. No access code is required. The live webcast can be accessed from the
Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fiscal 2024 STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year ended December 29, 2023. Fourth Quarter 2023 Overview Net sales up 19% to $76.3 million in the fourth quarter ICL sales up 22% to $74.6 million and ICL units up 19% Gross margin at 79.6% vs. 77.7% year ago Net income of $7.8 million vs. $6.8 million year ago